RNA-LNP Therapeutics Startup Axelyf Seeded to Conquer Delivery Challenges
Former Moderna executive Örn Almarsson, PhD, hopes to expand RNA therapeutic targets for autoimmune disease using proprietary lipid chemistry and AI
🧬 We are proud to announce our latest investment in Axelyf’s seed financing round, supporting their mission to advance next-generation RNA-LNP therapeutics.
“We’re not chasing science fiction, we’re contributing real solutions for tackling complex diseases,” said Örn Almarsson, PhD, CEO and co-founder of Axelyf, who previously led drug delivery efforts at Moderna during COVID-19 vaccine and therapeutics development.
As highlighted in Inside Precision Medicine, Axelyf is tackling one of the biggest challenges in RNA therapeutics: safe and effective delivery. Their proprietary technology, combined with assets acquired from 76Bio, Inc., enables superior potency, biodegradability, and extrahepatic delivery capabilities.
Other investors include Omega VC and Silfurberg.
“The company is a rare combination of cutting-edge science, proven leadership, and IP strength. This team can deliver on RNA medicine’s promise, and we are excited to be part of the journey,” said Arni Blöndal, Founding Partner at Brunnur Ventures, who joins Axelyf’s Board of Directors.
📖 Read the full release 👉https://lnkd.in/eTG4vfBn
Exceptional growth for start-up company hopp
The history of Icelandic VC funds and the Icelandic start-up ecosystem.
DTE has successfully managed to close a $16M Series A round in 2023
Oculis became dual-listed on the Nasdaq Iceland Main Market, complementing its existing listing on the Nasdaq Global Market in the U.S. (Nasdaq: OCS).
AviLabs has secured €8M in Series A funding to tackle airline passenger disruptions.
